Table 1.
The characteristics of all included studies.
| Study | Group | Therapeutic regimen | n, M/F | Age, years |
|---|---|---|---|---|
| Ji WP, 2011 | Experimental | Taohua Decoction (2 times/day, 1 month/course, 2 courses) | 52, 30/22 | 45.8±11.2 |
| Control | Sulfasalazine tablet 1 g (4 times/day, 1 month/course, 2 courses) | 34, 20/14 | 44.6±11.6 | |
| Jiang BS, 2019 | Experimental | Shenling Baizhu Powder + Taohua Decoction (2 times/day, 3 months/course, 1 course) | 57, 32/25 | 36.54±6.62 |
| Control | Salazine tablet 1g (4 times/day, 3 months/course, 1 course) | 57, 30/27 | 36.51±6.68 | |
| Luo FD, 2011 | Experimental | Shenling Baizhu Powder + Taohua Decoction (2 times/day, 10 days/course, 3 courses) | 35, NR | NR |
| Control | Sulfasalazine tablet 1–2 g (4 times/day, 10 days/course, 3 courses) | 33, NR | NR | |
| Qiu FL, 2016 | Experimental | Shenling Baizhu Powder + Taohua Decoction (2 times/day, 3 months/course, 1 course) | 60, 34/26 | 38.42±8.74 |
| Control | Salazine tablet 1 g (3 times/day, 3 months/course, 1 course) | 60, 36/24 | 39.25±8.84 | |
| Zheng FZ, 2006 | Experimental | Taohua Decoction (2 times/day, 1 month/course, 1 course) | 62, 38/24 | 37.2 |
| Control | Sulfasalazine tablet 1 g + prednisone 10 mg (4 times/day, 1 month/course, 1 course) | 40, 22/18 | 36.4 | |
| Zhong W, 2014 | Experimental | Taohua Decoction (2 times/day, 8 weeks/course, 1 course) | 45, 28/17 | 42.5±10.6 |
| Control | Oxalazine sodium capsule 1 g (4 times/day, 8 weeks/course, 1 course) | 45, 30/15 | 41.9±11.1 |
F – female; M – male; NR – not report.